menu
    • menu
    [{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Specialised Therapeutics \/ Ascendis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Ascendis Pharma"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Specialised Therapeutics \/ CanariaBio"}]

    Find Clinical Drug Pipeline Developments & Deals by Specialised Therapeutics

    Menu

    Specialised Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neratinib,Capecitabine,Loperamide Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Breast Cancer Therapy Approved in Thailand to Reduce Recurrence Risk

                            Details : Nerlynx (neratinib) is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2 overexpressed/amplified breast cancer.

                            Product Name : Nerlynx

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : Neratinib,Capecitabine,Loperamide Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Ascendis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Specialised Therapeutics Signs Agreement for Three Endocrinology Therapies

                            Details : Specialised Therapeutics will commercialize Ascendis' injectable pediatric growth hormone SKYTROFA, hypoparathyroidism treatment YORVIPATH, and investigational therapy TransCon CNP.

                            Product Name : Skytrofa

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            July 01, 2024

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Ascendis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : CanariaBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Specialised Therapeutics Signs Exclusive License Agreement with CanariaBio For New Ovarian Cancer Therapy

                            Details : Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.

                            Product Name : MAb-B43.13

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            December 10, 2023

                            Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : CanariaBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lymphoma Therapy Now Approved for Australian Patients with Diffuse Large B-Cell Lymphoma

                            Details : Monjuvi® and Minjuvi® (tafasitamab) is a humanized Fc-modified CD19 targeting immunotherapy used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

                            Product Name : Minjuvi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 28, 2023

                            Lead Product(s) : Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Global Sarcoma Therapy Now Approved for New Zealand Patients

                            Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...

                            Product Name : Yondelis

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 17, 2023

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ripretinib

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Therapy to Treat Rare Gastrointestinal Stromal Tumour Approved for New Zealand Patients

                            Details : Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.

                            Product Name : Qinlock

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 20, 2023

                            Lead Product(s) : Ripretinib

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Incyte Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Can...

                            Details : Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply of both products tafasitamab (sold as Monjuvi) and pemigatinib (Pemazyre) and ST will be responsible for regulatory, distribution and local marketing...

                            Product Name : Minjuvi

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 22, 2021

                            Lead Product(s) : Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Incyte Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : PharmaMar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore

                            Details : ZEPZELCA® (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers cascade of events that can affect activity of DNA binding proteins, including some transcription factors to treat 2L metastatic small cell lung cancer.

                            Product Name : Zepzelca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 22, 2021

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : PharmaMar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : PharmaMar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients

                            Details : ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC in Australia in more than 20 years. ZEPZELCA approval granted under a provisional regulatory pathway.

                            Product Name : Zepzelca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 14, 2021

                            Lead Product(s) : Lurbinectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : PharmaMar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GLOBAL Sarcoma Therapy Now Approved for Australian Patients

                            Details : The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-con...

                            Product Name : Yondelis

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 23, 2021

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth